株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性骨髄性白血病(AML、急性骨髄芽球性白血病) : パイプライン製品の分析

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232771
出版日 ページ情報 英文 1475 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.93円で換算しております。
Back to Top
急性骨髄性白血病(AML、急性骨髄芽球性白血病) : パイプライン製品の分析 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016
出版日: 2016年12月28日 ページ情報: 英文 1475 Pages
概要

急性骨髄性白血病(AML)は急性骨髄芽球性白血病としても知られており、血液および骨髄が侵されます。未熟な白血球が骨髄に蓄積すると、正常な血液細胞の生成が妨げられてしまいます。これらの細胞はその後血液の中に入り込み、全身に広がります。症侯は、疲労感、熱、出血、呼吸困難、体重の減少などが見られます。関係する素因としては、放射線や化学物質に曝されること、喫煙などが挙げられます。治療は化学療法や輸血、移植、薬物療法などで管理します。

当レポートでは、急性骨髄性白血病(AML)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

急性骨髄性白血病(AML、急性骨髄芽球性白血病)概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8869IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively.

Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview
  • Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
  • Drug Profiles
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2016
  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CrystalGenomics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime BV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Emercell SAS, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem SL, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FLX Bio Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FORMA Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gadeta BV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by HEC Pharm Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immatics Biotechnologies GmbH, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inflection Biosciences Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Io Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by IPD Therapeutics BV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma NV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Medivation Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus NV, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mesoblast Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by miRagen Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed SpA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nemucore Medical Innovations Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences Srl, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NewLink Genetics Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Omeros Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncopeptides AB, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTartis Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Panther Biotechnology Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Petra Pharma Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar SA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmascience Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen SpA, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Phylogica Ltd, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ProNAi Therapeutics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Inc, H2 2016
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2016

List of Figures

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2016
  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top